Combination vaccines containing DTPa–Hib: impact of IPV and coadministration of CRM197 conjugates

References

• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st Century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev.13, 302–317 (2000).
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria–tetanus–pertussis containing acellular pertussis. Lancet354(9195), 2063–2068 (1999).
   Google Scholar
• Heath PT, McVernon J. The UK Hib vaccine experience. Arch. Dis. Child86(6), 396–399 (2002).
   PubMed Web of Science ®Google Scholar
• Slack MH, Cade S, Schapira D et al. DT5aP–Hib–IPV and MCC vaccines: preterm infants’ response to accelerated immunization. Arch. Dis. Child90(4), 338–341 (2005).
   PubMed Web of Science ®Google Scholar
• Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics60(5), 730–737 (1977).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of imunologic tolerance or memory. Pediatrics74(5), 857–865 (1984).
   PubMed Web of Science ®Google Scholar
• Schneerson R, Robbins JB, Szu SC, Yang Y. Vaccines composed of polysaccharide-protein conjugates:current status, unanswered questions, and prospects for the future. In: Towards Better Carbohydrate Vaccines. Bell R, Torrigiani G (Eds). John Wiley & Sons, NY, USA307–331 (1987).
   Google Scholar
• Anderson PW, Pichichero ME, Stein EC et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM197. J. Immunol.142(7), 2464–2468 (1989).
   Google Scholar
• Berkowitz CD, Ward JI, Meier K et al. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J. Pediatr.110(4), 509–514 (1987).
   PubMed Web of Science ®Google Scholar
• Shackelford PG, Granoff DM, Nelson SJ, Scott MG, Smith DS, Nahm MH. Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide. J. Immunol.138(2), 587–592 (1987).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Sheetz KE, Nahm MH, Madassery JV, Shackelford PG. Further immunologic evaluation of children who develop Haemophilus disease despite previous vaccination with type b polysaccharide vaccine. Monogr. Allergy23, 256–268 (1988).
   PubMedGoogle Scholar
• Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J. Pediatr.111(1), 22–27 (1987).
   PubMed Web of Science ®Google Scholar
• Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals22(4), 397–402 (1994).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Shackelford PG, Holmes SJ, Lucas AH. Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new λ light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group. J. Clin. Invest.91(3), 788–796 (1993).
   PubMedGoogle Scholar
• Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J.12(6), 484–492 (1993).
   PubMed Web of Science ®Google Scholar
• Eskola J, Käyhty H, Peltola H et al. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine. Lancet1(8439), 1184–1186 (1985).
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J. Pediatr.120(2 Pt 1), 184–189 (1992).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Lagergård T, Käyhty H. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: a follow-up of 2 different regimens of infant vaccination. Scand. J. Infect. Dis.28(5), 519–523 (1996).
   PubMed Web of Science ®Google Scholar
• Jelonek MT, Chang SJ, Chiu CY, Park MK, Nahm MH, Ward JI. Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide. Infect. Immun.61(12), 5345–5350 (1993).
   Google Scholar
• Decker MD, Edwards KM, Bradley R, Palmer P. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type b vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. J. Pediatr.122(3), 410–413 (1993).
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA267(11), 1489–1494 (1992).
   PubMed Web of Science ®Google Scholar
• Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J. Immunol.154(8), 4195–4202 (1995).
   PubMed Web of Science ®Google Scholar
• Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N. Engl. J. Med.323(20), 1393–1401 (1990).
   PubMed Web of Science ®Google Scholar
• Adams WG, Deaver KA, Cochi SL et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA269(2), 221–226 (1993).
   PubMed Web of Science ®Google Scholar
• Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg. Infect. Dis.2(3), 176–182 (1996).
   PubMed Web of Science ®Google Scholar
• Takala AK, Eskola J, Leinonen M et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis.164(5), 982–986 (1991).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J. Pediatr.122(4), 517–523 (1993).
   PubMed Web of Science ®Google Scholar
• Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J. Infect. Dis.177(6), 1758–1761 (1998).
   PubMed Web of Science ®Google Scholar
• Kauppi M, Eskola J, Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J.14(4), 286–294 (1995).
   PubMed Web of Science ®Google Scholar
• Barbour ML, Booy R, Crook DW et al.Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide–CRM197 (HbOC) conjugate vaccine. Pediatr. Infect. Dis. J.12(6), 478–484 (1993).
   PubMed Web of Science ®Google Scholar
• Mohle-Boetani JC, Ajello G, Breneman E et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J.12(7), 589–593 (1993).
   PubMed Web of Science ®Google Scholar
• Santosham M, Reid R, Ambrosino DM et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med.317, 923–929 (1987)
   PubMed Web of Science ®Google Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis.147, 1100 (1983).
   PubMed Web of Science ®Google Scholar
• Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis.149(6), 1034–1035 (1984).
   PubMed Web of Science ®Google Scholar
• Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin. Infect. Dis.33(Suppl. 4), S278–S287 (2001).
   PubMed Web of Science ®Google Scholar
• Singleton R, Hammitt L, Hennessy T et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics118(2), e421–e429 (2006).
   Google Scholar
• Pichichero ME, Voloshen T, Zajac D, Passador S. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria–tetanus–acellular pertussis–Hib–hepatitis B combined vaccine in infants. J. Infect. Dis.180(4), 1390–1393 (1999).
   PubMed Web of Science ®Google Scholar
• Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine19(17–19), 2280–2285 (2001).
   PubMed Web of Science ®Google Scholar
• Eskola J, Käyhty H, Takala AK et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N. Engl. J. Med.323(20), 1381–1387 (1990).
   PubMed Web of Science ®Google Scholar
• Denoël PA, Goldblatt D, Vleeschauwer I, Jacquet JM, Pichichero ME, Poolman JT. Quality of the Haemophilus influenzae type b antibody response induced by DTPa/Hib combination vaccines. Clin. Vaccine Immunol.14(10), 1362–1369 (2007).
   PubMedGoogle Scholar
• Bredius RG, Driedijk PC, Schouten MF, Weening RS, Out TA. Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid. Infect. Immun.60(11), 4838–4847 (1992).
   Google Scholar
• Amir J, Scott MG, Nahm MH, Granoff DM. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J. Infect. Dis.162(1), 163–171 (1990).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Miller E, McCloskey N, Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ316, 1569–1570 (1998).
   Google Scholar
• Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect. Dis.183(1), 160–163 (2001).
   PubMed Web of Science ®Google Scholar
• Pallares DE, Figueroa JE, Densen P, Giclas PC, Marshall GS. Invasive Haemophilus influenzae type b infection in a child with familial deficiency of the beta subunit of the eighth component of complement. J. Pediatr.128(1), 102–103 (1996).
   Google Scholar
• Musher D, Goree A, Murphy T et al. Immunity to Haemophilus influenzae type b in young adults: correlation of bactericidal and opsonizing activity of serum with antibody to polyribosylribitol phosphate and lipooligosaccharide before and after vaccination. J. Infect. Dis.154(6), 935–943 (1986).
   Google Scholar
• Schmitt HJ, Zepp F, Müschenborn S et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria–tetanus–toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur. J. Pediatr.157(3), 208–214 (1998).
   PubMed Web of Science ®Google Scholar
• Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae–tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin. Infect. Dis.28(5), 995–1001 (1999).
   PubMed Web of Science ®Google Scholar
• Mills E, Gold R, Thipphawong J et al. Safety and immunogenicity of a combined five-component pertussis–diphtheria–tetanus–inactivated poliomyelitis–Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine16(6), 576–585 (1998).
   PubMed Web of Science ®Google Scholar
• Lin TY, Wang YH, Chang LY et al. A fully liquid diphtheria–tetanus–five component acellular pertussis–inactivated poliomyelitis–Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int. J. Infect. Dis.11(2), 129–136 (2007).
   PubMed Web of Science ®Google Scholar
• Halperin SA, McDonald J, Samson L et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin. Invest. Med.25(6), 243–251 (2002).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, von Kries R, Hassenpflug B et al.Haemophilus influenzae type b disease: impact and effectiveness of diphtheria–tetanus toxoids–acellular pertussis (–inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr. Infect. Dis. J.20(8), 767–774 (2001).
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria–tetanus toxoids–acellular pertussis/Haemophilus influenzae type b and diphtheria–tetanus toxoids–acellular pertussis–inactivated poliovirus/H.influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J.23(10), 944–950 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson NG, Ruggeberg JU, Balfour GF et al.Haemophilus influenzae type b reemergence after combination immunization. Emerg. Infect. Dis.12(6), 937–941 (2006).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Käyhty H, Selstam U, Iwarson S. Studies on a Hib–tetanus toxoid conjugate vaccine: effects of coadministered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine18(5–6), 468–478 (2000).
   Google Scholar
• Yeh SH, Ward JI, Partridge S et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr. Infect. Dis. J.20(10), 973–980 (2001).
   PubMedGoogle Scholar
• Blatter MM, Reisinger KS, Terwelp DR, DelBuono FJ, Howe BJ. Immunogenicity of a combined diphtheria–tetanus–acellular pertussis (DT–tricomponent Pa)–hepatitis B (HB)–inactivated poliovirus (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants. Presented at: American Pediatric Society and the Society for Pediatric Research. LA, USA. 1–5, May, 1998 (Abstract 813).
   Google Scholar
• Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa–HBV–IPV/Hib vaccine compared to separate concomitant injections of DTPa–IPV/Hib and HBV vaccines, when administered according to a 3, 5–11 month vaccination schedule. Eur. J. Pediatr.161(11), 581–587 (2002).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Bernstein H, Blatter MM, Schuerman L et al. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis b, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J. Pediatr.151(1), 43–49 (49e1–49e2) (2007).
   PubMedGoogle Scholar
• Arístegui J, Dal-Ré R, Díez-Delgado J et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa–HBV–IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa–IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4–6 months of age. Vaccine21(25–26), 3593–3600 (2003).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Englund JA, Bernstein DI et al. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria–tetanus–acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr. Infect. Dis. J.19(5), 417–423 (2000).
   PubMed Web of Science ®Google Scholar
• Rowe J, Yerkovich ST, Richmond P et al. Th2-associated local reactions to the acellular diphtheria–tetanus–pertussis vaccine in 4- to 6-year-old children. Infect. Immun.73(12), 8130–8135 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology113(2), 163–174 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson P, Ingram DL, Pichichero ME, Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr. Infect. Dis. J.19(7), 589–591 (2000).
   PubMedGoogle Scholar
• McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet361(9368), 1521–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. NY Acad. Sci.754, 35–47 (1995).
   PubMed Web of Science ®Google Scholar
• Heath PT, Booy R, Azzopardi HJ et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA284(18), 2334–2340 (2000).
   PubMed Web of Science ®Google Scholar
• Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunization programme, and changes to the meningitis C and Hib schedules. Eurosurveillance11(3), E060302.4 (2006).
   Google Scholar
• Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunization with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet349(9060), 1197–1202 (1997).
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Goldblatt D. Conjugate Hib vaccines. Lancet361(9355), 360–361 (2003).
   PubMed Web of Science ®Google Scholar
• Mäkelä PH, Käyhty H. Evolution of conjugate vaccines. Expert Rev. Vaccines1(3), 399–410 (2002).
   PubMedGoogle Scholar
• von Kries R, Böhm O, Windfuhr A. Haemophilus influenzae b-vaccination: the urgency for timely vaccination. Eur. J. Pediatr.156(4), 282–287 (1997).
   Google Scholar
• Heath PT, Booy R, Griffiths H et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin. Infect. Dis.31(4), 973–980 (2000).
   PubMed Web of Science ®Google Scholar
• Slack MH, Schapira D, Thwaites RJ et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria–tetanus toxoids–acellular pertussis–Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis.184(12), 1617–1620 (2001).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Richmond P, Millard E, Thornton C, Miller E.The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J. Infect. Dis.180(2), 538–541 (1999).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.25(4), 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E.Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3–4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine24(2), 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Immunogenicity and Reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C and Y–tetanus toxoid conjugate (Hib–MenCY–TT) vaccine administered as a primary at 2, 3–4 months and as a booster at second year of life. Presented at: 15th International Pathogenic Neisseria Conference, Cairns, Australia, 10–15 September, 2006. (Abstract).
   Google Scholar
• Schmitt HJ, Maechler G, Habermehl P, et al. Immunogenicity, reactogenicity and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol.14(4), 426–434 (2007).
   PubMedGoogle Scholar
• Tejedor JC, Omeãaca F, García-Sicilia J et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio–Haemophilus influenzae type b vaccine co-administered with a meningococcal C conjugate vaccine. Pediatr. Infect. Dis. J.23(12), 1109–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV–IPV/Hib combination vaccine in healthy infants. Vaccine24(22), 4727–4736 (2006).
   PubMedGoogle Scholar
• Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheria–tetanus–three-component acellular pertussis–hepatitis B–inactivated polio virus–Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr. Infect. Dis. J.24(1), 70–77 (2005).
   PubMed Web of Science ®Google Scholar
• Tozzi AE, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giudice ML. Can hexavalent vaccines be simultaneously administered with pneumococcal or meningococcal conjugate vaccines? Hum. Vaccin.23, 3–(6) (2007).
   Google Scholar
• Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP–T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine24(12), 2057–2064 (2006).
   PubMed Web of Science ®Google Scholar
• Olivier C, Liese JG, Stojanov S et al. Immunogenicity and safety of the 7-valent pneumococcal conjugate vaccine (7vPNC–Prevenar) coadministered with a hexavalent DTaP–IPV–HBV–Hib Vaccine (Hexavac). Poster G-836. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA, 27–30, September, 2002.
   Google Scholar
• Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun.66(5), 2093–2098 (1998).
   PubMed Web of Science ®Google Scholar
• Dagan R, Goldblatt D, Maleckar JR, Yaïch M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun.72(9), 5383–5391 (2004).
   PubMed Web of Science ®Google Scholar
• Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP–T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunization schedule, may modify the serum anti-PRP antibody responses. Curr. Med. Res. Opin.17(3), 197–209 (2001).
   PubMed Web of Science ®Google Scholar
• Spanjaard L, van den Hof S, de Melker HE, Vermeer-de Bondt PE, van der Ende A, Rijkers GT. Increase in the number of invasive Haemophilus influenzae type b infections. Ned. Tijdschr. Geneeskd.149(49), 2738–2742 (2005).
   PubMedGoogle Scholar
• McVernon J, Howard AJ, Slack MP, Ramsay ME. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol. Infect.132(4), 765–767 (2004).
   PubMed Web of Science ®Google Scholar
• Pabst HF, Spady DW. Effect of breast-feeding on antibody response to conjugate vaccine. Lancet336(8710), 269–270 (1990).
   PubMed Web of Science ®Google Scholar
• Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine19(23–24), 3043–3050 (2001).
   PubMed Web of Science ®Google Scholar
• Madore DV, Johnson-Kraines CL, Rothstein EP, Smith DH. Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates. Curr. Med. Res. Opin.15(2), 105–112 (1999).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Voloshen T, Passador S. Kinetics of booster responses to Haemophilus influenzae type B conjugate after combined diphtheria–tetanus–acelluar pertussis–Haemophilus influenzae type b vaccination in infants. Pediatr. Infect. Dis. J.18(12), 1106–1108 (1999).
   PubMed Web of Science ®Google Scholar
• Lucas AH, Granoff DM. Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr. Infect. Dis. J.20(3), 235–239 (2001).
   PubMed Web of Science ®Google Scholar
• Heath PT, Booy R, McVernon J et al. Hib vaccination in infants born prematurely. Arch. Dis. Child.88(3), 206–210 (2003).
   PubMed Web of Science ®Google Scholar
• Corn PG, Anders J, Takala AK, Käyhty H, Hoiseth SK. Genes involved in Haemophilus influenzae type b capsule expression are frequently amplified. J. Infect. Dis.167(2), 356–364 (1993).
   Web of Science ®Google Scholar
• Cerquetti M, Cardines R, Ciofi degli Atti ML et al. Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure. J. Infect. Dis.192(5), 819–823 (2005).
   PubMed Web of Science ®Google Scholar
• Schouls LM, van der Ende A, van de Pol et al. Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in The Netherlands. J. Clin. Microbiol.43(6), 2741–2749 (2005).
   PubMed Web of Science ®Google Scholar
• Aracil B, Slack M, Pérez-Vázquez M, Román F, Ramsay M, Campos J. Molecular epidemiology of Haemophilus influenzae type b causing vaccine failures in the United Kingdom. J. Clin. Microbiol.44(5), 1645–1649 (2006).
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on the recommended use of pentavalent and hexavalent vaccines. Can. Commun. Dis. Rep.33(Suppl. 3) 1–16 (2007).
   Google Scholar
• Buttery JP, Riddell A, McVernon J et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA293(14), 1751–1758 (2005).
   PubMed Web of Science ®Google Scholar
• Choo S, Seymour L, Morris R et al. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr. Infect. Dis. J.19(9), 854–862 (2000).
   PubMed Web of Science ®Google Scholar
• Lagos R, Horwitz I, Toro J et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP–T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr. Infect. Dis. J.15(3), 216–222 (1996).
   PubMed Web of Science ®Google Scholar
• Booy R, Hodgson S, Carpenter L et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP–T. Lancet344(8919), 362–366 (1994).
   PubMed Web of Science ®Google Scholar
• Peltola H, Eskola J, Käyhty H, Takala AK, Mäkelä PH. Clinical comparison of the Haemophilus influenzae type b polysaccharide–diphtheria toxoid and the oligosaccharide–CRM197 protein vaccines in infancy. Arch. Pediatr. Adolesc. Med.148(6), 620–625 (1994).
   PubMedGoogle Scholar
• Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr. Infect. Dis. J.10(2), 97–104 (1991).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Lampert D et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr. Infect. Dis. J.10(2), 92–96 (1991).
   PubMed Web of Science ®Google Scholar
• Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet349(9060), 1191–1197 (1997).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Selstam U et al. Safety and immunogenicity of a combined diphtheria–tetanus–acellular pertussis–inactivated polio vaccine–Haemophilus influenzae type b vaccine administered at 2–4-6–13 or 3–5-12 months of age. Pediatr. Infect. Dis. J.17(11), 1026–1033 (1998).
   PubMed Web of Science ®Google Scholar
• Mallet E, Fabre P, Pines E et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J.19(12), 1119–1127 (2000).
   PubMed Web of Science ®Google Scholar
• Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Use of lidocaine–prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr. Infect. Dis. J.21(5), 399–405 (2002).
   PubMed Web of Science ®Google Scholar
• Kitchin N, Southern J, Morris R et al. Evaluation of a diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3–4 months of age. Arch. Dis. Child.92, 11–16 (2007).
   Google Scholar
• Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria–tetanus–acellular pertussis–hepatitis B virus–inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J. Pediatr.137(3), 304–312 (2000).
   PubMed Web of Science ®Google Scholar